Stock Market News

Biohaven stock rises following FDA review and Deutsche Bank's buy rating

Feb 11, 2025 - 14:30
 0
Biohaven stock rises following FDA review and Deutsche Bank's buy rating
Read More

Tags:

Previous Article

Fluence Energy: Sell On Abysmal Quarter And Disappointing Outlook

Next Article

Anterix stock jumps on strategic review announcement

Related Posts

Marriott's 2025 profit forecast falls short of expectations on China performance

Marriott's 2025 profit forecast falls short of expectat...

Feb 11, 2025  0

Mobileye: BofA lifts rating on reduced downside risks, ...

Feb 10, 2025  0

China's BYD to sell 21 models with its 'God's Eye' smart driving tech

China's BYD to sell 21 models with its 'God's Eye' smar...

Feb 10, 2025  0